NV-BITSENSING
12.1.2021 13:02:35 CET | Business Wire | Press release
bitsensing , a South Korean radar technology startup, introduces the new mini Healthcare Radar, mini-H , the smallest high-resolution 60GHz IoT Radar sensor in the lineup. The innovation behind the mini-H demonstrates the company’s industry leading expertise in designing and building cutting edge radar technology that can transform healthcare, automotive, mobility, smart home, security, and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005325/en/
Dr. Jae-Eun Lee, CEO of bitsensing, a seasoned engineer in radar technology and formerly a part of the automotive world at Mando Corp., knows what it takes to create a safe and conveniently connected world. “Revolutionary technologies such as mini-H are propelling what is possible in all facets of our daily lives,” says Lee. “We at bitsensing are committed to integrating these groundbreaking radar technologies to help build smart lives and smart cities which ultimately elevates the quality of life for all.”
The advanced mini-H sensor attaches to the wall and can detect, in real-time, presence, movement, breathing or lack thereof, and falls by measuring breathing patterns and pulsating vessels without the use of intrusive cameras or wearables.
Specifically designed for a more intelligent and safer monitoring system for telehealth, mini-H can be used in dark or wet places and works regardless of clothes or blankets. The Bluetooth and WiFi communication module allows for a seamless transfer of data from the radar to dashboards or the app for easy tracking. This fully wireless product makes it quick and easy to implement software advancements, ensuring the product is always up to date. The sleek, compact aesthetic of the product also allows for an easy integration while the plug and play style provides instant monitoring of activities with the option to adjust settings for optimal personalization.
As a leading radar solution company, bitsensing offers complete end to end services, creating customizable radars like the mini-H that exceed industry standards in convenience and security. The nimble structure of bitsensing allows the team to deliver powerful products quickly while working directly with end customers across a large range of industries to ensure satisfaction and broaden their horizons of what is possible in a smart life.
CES attendees can visit bitsensing’s virtual booth to learn more about the mini-H from January 11-14, 2021. To view the mini-H informational product video, please visit here . If you are interested in learning more about our radar solution offerings, please visit www.bitsensing.com .
mini-H Product Specifications
Specs subject to change without notice. All functionality, features, specifications and other product information provided in this document including, but not limited to, the benefits, design, pricing, components, performance, availability, and capabilities of the product are subject to change without notice.
General Spec |
|
Centered Frequency |
61 GHz |
Bandwidth |
3.75 GHz |
Communication Interface |
WiFi or Bluetooth, RS485 |
Coverage Spec |
|
Detection Range |
0.2m ~ 2.5m |
Field of View |
±60° (Azimuth), ±60° (Elevation) |
Feature |
Moving, Falling, Presence, Apnea |
Vital Sign |
Respiration* |
Resolution |
0.04m |
Electrical Spec |
|
Operating Voltage |
7V ~ 14V |
Current Consumption |
Max 3W |
Mechanical Spec |
|
Dimensions |
50 x 50 x 15 mm |
Weight |
100g** |
Connector |
Open terminal Cable |
Environment Spec |
|
Operating Temperature |
-20 ~ +85 °C |
* The data driven by respiration detection may be limited and is designed to be used for apnea detection |
** The weight is without cable |
About bitsensing
bitsensing is an imaging radar technology company committed to building safer smart cities and elevating connected living by designing cutting-edge sensor fusions and AI solutions bringing an unprecedented level of intelligence to smart living. Founded in 2018 by seasoned automotive experts, bitsensing is one of the only startups delivering optimal technologies that meet and exceed the high level of safety and convenience that the industry demands. bitsensing is transforming possibilities to bring democratization of smart life in healthcare, automotive, mobility, smart home, security, and beyond.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom